Q-omics provides the consensus-scored SAP18P3 profile across patient tissues and cancer cell-line models. SAP18P3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SAP18P3 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, SAP18P3 RNA expression shows 6,792 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, COAD, and STAD as cancer lineages where SAP18P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAP18P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAP18P3 survival associations across molecular data types. SAP18P3 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAP18P3 RNA expression–survival associations across cancer types. High SAP18P3 expression shows unfavorable associations in KIRP, LUSC, LGG, KICH and MESO, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for SAP18P3 RNA expression.
This table summarizes SAP18P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SAP18P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAP18P3 shows higher tumor expression in COAD, LUAD, UCEC, PRAD, STAD and KIRC. The COAD box plot shows higher SAP18P3 RNA expression in tumor versus normal tissue (log2 FC = +0.211, t-test p = .001).
This table shows molecular features associated with SAP18P3 in patient tissues and cancer cell lines. In patient samples, SAP18P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
